 | • レポートコード：GIR-2104Z10042 • 出版社/出版日：GlobalInfoResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、121ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥487,200 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥730,800 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥974,400 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、糖尿病用非インスリン療法のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。糖尿病用非インスリン療法の種類別市場規模（α-グルコシダーゼ阻害剤、アミリンアゴニスト、ビグアニド、ジペプチジルペプチダーゼ-4（DPP4）阻害剤、グリニド/メグリチニド、GLP-1アナログ/ GLP-1アゴニスト、ナトリウム-グルコース共輸送体2（SGLT2）阻害剤、スルホニル尿素、チアゾリジンジオン、その他）、用途別市場規模（モニタリング、診断、治療、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・糖尿病用非インスリン療法の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：GSK、Eli Lilly、Sumitomo Dainippon Pharma、Intarcia Therapeutics、Servier、Pfizer、Merck、Dong-A Pharmaceutical、Luye Pharma Group、Eurofarma、Geropharm、Alkem Labs、SatRx、Jiangsu Hansoh Pharmaceutical、Novo Nordisk、Emisphere、Uni-Bio Science Group、Takeda、3SBio、Jiangsu Hengrui Medicine ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：α-グルコシダーゼ阻害剤、アミリンアゴニスト、ビグアニド、ジペプチジルペプチダーゼ-4（DPP4）阻害剤、グリニド/メグリチニド、GLP-1アナログ/ GLP-1アゴニスト、ナトリウム-グルコース共輸送体2（SGLT2）阻害剤、スルホニル尿素、チアゾリジンジオン、その他 ・用途別分析2016年-2026年：モニタリング、診断、治療、その他 ・糖尿病用非インスリン療法の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・糖尿病用非インスリン療法のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・糖尿病用非インスリン療法のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・糖尿病用非インスリン療法の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・糖尿病用非インスリン療法の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Non-Insulin Therapies for Diabetes market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Non-Insulin Therapies for Diabetes size is estimated to be USD 42860 million in 2025 from USD 30910 million in 2019, with a change XX% between 2019 and 2020. The global Non-Insulin Therapies for Diabetes market size is expected to grow at a CAGR of 8.5% for the next five years.
Market segmentation
Non-Insulin Therapies for Diabetes market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Alpha-glucosidase Inhibitors
Amylin Agonists
Biguanides
Dipeptidyl Peptidase-4 (DPP4) Inhibitors
Glinides / Meglitinides
GLP-1 Analogs / GLP-1 Agonists
Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
Sulfonylureas
Thiazolidinediones
Others
Market segment by Application, can be divided into
Monitoring
Diagnosis
Treatment
Others
Market segment by players, this report covers
GSK
Eli Lilly
Sumitomo Dainippon Pharma
Intarcia Therapeutics
Servier
Pfizer
Merck
Dong-A Pharmaceutical
Luye Pharma Group
Eurofarma
Geropharm
Alkem Labs
SatRx
Jiangsu Hansoh Pharmaceutical
Novo Nordisk
Emisphere
Uni-Bio Science Group
Takeda
3SBio
Jiangsu Hengrui Medicine
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of Non-Insulin Therapies for Diabetes
1.2 Classification of Non-Insulin Therapies for Diabetes by Type
1.2.1 Overview: Global Non-Insulin Therapies for Diabetes Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Non-Insulin Therapies for Diabetes Revenue Market Share by Type in 2020
1.2.3 Alpha-glucosidase Inhibitors
1.2.4 Amylin Agonists
1.2.5 Biguanides
1.2.6 Dipeptidyl Peptidase-4 (DPP4) Inhibitors
1.2.7 Glinides / Meglitinides
1.2.8 GLP-1 Analogs / GLP-1 Agonists
1.2.9 Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
1.2.10 Sulfonylureas
1.2.11 Thiazolidinediones
1.2.12 Others
1.3 Global Non-Insulin Therapies for Diabetes Market by Application
1.3.1 Overview: Global Non-Insulin Therapies for Diabetes Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Monitoring
1.3.3 Diagnosis
1.3.4 Treatment
1.3.5 Others
1.4 Global Non-Insulin Therapies for Diabetes Market Size & Forecast
1.5 Global Non-Insulin Therapies for Diabetes Market Size and Forecast by Region
1.5.1 Global Non-Insulin Therapies for Diabetes Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Non-Insulin Therapies for Diabetes Market Size by Region, (2016-2021)
1.5.3 North America Non-Insulin Therapies for Diabetes Market Size and Prospect (2016-2026)
1.5.4 Europe Non-Insulin Therapies for Diabetes Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size and Prospect (2016-2026)
1.5.6 South America Non-Insulin Therapies for Diabetes Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Non-Insulin Therapies for Diabetes Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Non-Insulin Therapies for Diabetes Market Drivers
1.6.2 Non-Insulin Therapies for Diabetes Market Restraints
1.6.3 Non-Insulin Therapies for Diabetes Trends Analysis
2 Company Profiles
2.1 GSK
2.1.1 GSK Details
2.1.2 GSK Major Business
2.1.3 GSK Non-Insulin Therapies for Diabetes Product and Solutions
2.1.4 GSK Non-Insulin Therapies for Diabetes Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 GSK Recent Developments and Future Plans
2.2 Eli Lilly
2.2.1 Eli Lilly Details
2.2.2 Eli Lilly Major Business
2.2.3 Eli Lilly Non-Insulin Therapies for Diabetes Product and Solutions
2.2.4 Eli Lilly Non-Insulin Therapies for Diabetes Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Eli Lilly Recent Developments and Future Plans
2.3 Sumitomo Dainippon Pharma
2.3.1 Sumitomo Dainippon Pharma Details
2.3.2 Sumitomo Dainippon Pharma Major Business
2.3.3 Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Product and Solutions
2.3.4 Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Sumitomo Dainippon Pharma Recent Developments and Future Plans
2.4 Intarcia Therapeutics
2.4.1 Intarcia Therapeutics Details
2.4.2 Intarcia Therapeutics Major Business
2.4.3 Intarcia Therapeutics Non-Insulin Therapies for Diabetes Product and Solutions
2.4.4 Intarcia Therapeutics Non-Insulin Therapies for Diabetes Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Intarcia Therapeutics Recent Developments and Future Plans
2.5 Servier
2.5.1 Servier Details
2.5.2 Servier Major Business
2.5.3 Servier Non-Insulin Therapies for Diabetes Product and Solutions
2.5.4 Servier Non-Insulin Therapies for Diabetes Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Servier Recent Developments and Future Plans
2.6 Pfizer
2.6.1 Pfizer Details
2.6.2 Pfizer Major Business
2.6.3 Pfizer Non-Insulin Therapies for Diabetes Product and Solutions
2.6.4 Pfizer Non-Insulin Therapies for Diabetes Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Pfizer Recent Developments and Future Plans
2.7 Merck
2.7.1 Merck Details
2.7.2 Merck Major Business
2.7.3 Merck Non-Insulin Therapies for Diabetes Product and Solutions
2.7.4 Merck Non-Insulin Therapies for Diabetes Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Merck Recent Developments and Future Plans
2.8 Dong-A Pharmaceutical
2.8.1 Dong-A Pharmaceutical Details
2.8.2 Dong-A Pharmaceutical Major Business
2.8.3 Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Product and Solutions
2.8.4 Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Dong-A Pharmaceutical Recent Developments and Future Plans
2.9 Luye Pharma Group
2.9.1 Luye Pharma Group Details
2.9.2 Luye Pharma Group Major Business
2.9.3 Luye Pharma Group Non-Insulin Therapies for Diabetes Product and Solutions
2.9.4 Luye Pharma Group Non-Insulin Therapies for Diabetes Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Luye Pharma Group Recent Developments and Future Plans
2.10 Eurofarma
2.10.1 Eurofarma Details
2.10.2 Eurofarma Major Business
2.10.3 Eurofarma Non-Insulin Therapies for Diabetes Product and Solutions
2.10.4 Eurofarma Non-Insulin Therapies for Diabetes Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Eurofarma Recent Developments and Future Plans
2.11 Geropharm
2.11.1 Geropharm Details
2.11.2 Geropharm Major Business
2.11.3 Geropharm Non-Insulin Therapies for Diabetes Product and Solutions
2.11.4 Geropharm Non-Insulin Therapies for Diabetes Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 Geropharm Recent Developments and Future Plans
2.12 Alkem Labs
2.12.1 Alkem Labs Details
2.12.2 Alkem Labs Major Business
2.12.3 Alkem Labs Non-Insulin Therapies for Diabetes Product and Solutions
2.12.4 Alkem Labs Non-Insulin Therapies for Diabetes Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Alkem Labs Recent Developments and Future Plans
2.13 SatRx
2.13.1 SatRx Details
2.13.2 SatRx Major Business
2.13.3 SatRx Non-Insulin Therapies for Diabetes Product and Solutions
2.13.4 SatRx Non-Insulin Therapies for Diabetes Revenue, Gross Margin and Market Share (2019-2021)
2.13.5 SatRx Recent Developments and Future Plans
2.14 Jiangsu Hansoh Pharmaceutical
2.14.1 Jiangsu Hansoh Pharmaceutical Details
2.14.2 Jiangsu Hansoh Pharmaceutical Major Business
2.14.3 Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Product and Solutions
2.14.4 Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Revenue, Gross Margin and Market Share (2019-2021)
2.14.5 Jiangsu Hansoh Pharmaceutical Recent Developments and Future Plans
2.15 Novo Nordisk
2.15.1 Novo Nordisk Details
2.15.2 Novo Nordisk Major Business
2.15.3 Novo Nordisk Non-Insulin Therapies for Diabetes Product and Solutions
2.15.4 Novo Nordisk Non-Insulin Therapies for Diabetes Revenue, Gross Margin and Market Share (2019-2021)
2.15.5 Novo Nordisk Recent Developments and Future Plans
2.16 Emisphere
2.16.1 Emisphere Details
2.16.2 Emisphere Major Business
2.16.3 Emisphere Non-Insulin Therapies for Diabetes Product and Solutions
2.16.4 Emisphere Non-Insulin Therapies for Diabetes Revenue, Gross Margin and Market Share (2019-2021)
2.16.5 Emisphere Recent Developments and Future Plans
2.17 Uni-Bio Science Group
2.17.1 Uni-Bio Science Group Details
2.17.2 Uni-Bio Science Group Major Business
2.17.3 Uni-Bio Science Group Non-Insulin Therapies for Diabetes Product and Solutions
2.17.4 Uni-Bio Science Group Non-Insulin Therapies for Diabetes Revenue, Gross Margin and Market Share (2019-2021)
2.17.5 Uni-Bio Science Group Recent Developments and Future Plans
2.18 Takeda
2.18.1 Takeda Details
2.18.2 Takeda Major Business
2.18.3 Takeda Non-Insulin Therapies for Diabetes Product and Solutions
2.18.4 Takeda Non-Insulin Therapies for Diabetes Revenue, Gross Margin and Market Share (2019-2021)
2.18.5 Takeda Recent Developments and Future Plans
2.19 3SBio
2.19.1 3SBio Details
2.19.2 3SBio Major Business
2.19.3 3SBio Non-Insulin Therapies for Diabetes Product and Solutions
2.19.4 3SBio Non-Insulin Therapies for Diabetes Revenue, Gross Margin and Market Share (2019-2021)
2.19.5 3SBio Recent Developments and Future Plans
2.20 Jiangsu Hengrui Medicine
2.20.1 Jiangsu Hengrui Medicine Details
2.20.2 Jiangsu Hengrui Medicine Major Business
2.20.3 Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Product and Solutions
2.20.4 Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Revenue, Gross Margin and Market Share (2019-2021)
2.20.5 Jiangsu Hengrui Medicine Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Non-Insulin Therapies for Diabetes Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 5 Non-Insulin Therapies for Diabetes Players Market Share
3.2.2 Top 10 Non-Insulin Therapies for Diabetes Players Market Share
3.2.3 Market Competition Trend
3.3 Non-Insulin Therapies for Diabetes Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Non-Insulin Therapies for Diabetes Revenue and Market Share by Type (2016-2021)
4.2 Global Non-Insulin Therapies for Diabetes Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Non-Insulin Therapies for Diabetes Revenue Market Share by Application (2016-2021)
5.2 Non-Insulin Therapies for Diabetes Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Non-Insulin Therapies for Diabetes Revenue by Type (2016-2026)
6.2 North America Non-Insulin Therapies for Diabetes Revenue by Application (2016-2026)
6.3 North America Non-Insulin Therapies for Diabetes Market Size by Country
6.3.1 North America Non-Insulin Therapies for Diabetes Revenue by Country (2016-2026)
6.3.2 United States Non-Insulin Therapies for Diabetes Market Size and Forecast (2016-2026)
6.3.3 Canada Non-Insulin Therapies for Diabetes Market Size and Forecast (2016-2026)
6.3.4 Mexico Non-Insulin Therapies for Diabetes Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Non-Insulin Therapies for Diabetes Revenue by Type (2016-2026)
7.2 Europe Non-Insulin Therapies for Diabetes Revenue by Application (2016-2026)
7.3 Europe Non-Insulin Therapies for Diabetes Market Size by Country
7.3.1 Europe Non-Insulin Therapies for Diabetes Revenue by Country (2016-2026)
7.3.2 Germany Non-Insulin Therapies for Diabetes Market Size and Forecast (2016-2026)
7.3.3 France Non-Insulin Therapies for Diabetes Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Non-Insulin Therapies for Diabetes Market Size and Forecast (2016-2026)
7.3.5 Russia Non-Insulin Therapies for Diabetes Market Size and Forecast (2016-2026)
7.3.6 Italy Non-Insulin Therapies for Diabetes Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Non-Insulin Therapies for Diabetes Revenue by Type (2016-2026)
8.2 Asia-Pacific Non-Insulin Therapies for Diabetes Revenue by Application (2016-2026)
8.3 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Region
8.3.1 Asia-Pacific Non-Insulin Therapies for Diabetes Revenue by Region (2016-2026)
8.3.2 China Non-Insulin Therapies for Diabetes Market Size and Forecast (2016-2026)
8.3.3 Japan Non-Insulin Therapies for Diabetes Market Size and Forecast (2016-2026)
8.3.4 South Korea Non-Insulin Therapies for Diabetes Market Size and Forecast (2016-2026)
8.3.5 India Non-Insulin Therapies for Diabetes Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Non-Insulin Therapies for Diabetes Market Size and Forecast (2016-2026)
8.3.7 Australia Non-Insulin Therapies for Diabetes Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Non-Insulin Therapies for Diabetes Revenue by Type (2016-2026)
9.2 South America Non-Insulin Therapies for Diabetes Revenue by Application (2016-2026)
9.3 South America Non-Insulin Therapies for Diabetes Market Size by Country
9.3.1 South America Non-Insulin Therapies for Diabetes Revenue by Country (2016-2026)
9.3.2 Brazil Non-Insulin Therapies for Diabetes Market Size and Forecast (2016-2026)
9.3.3 Argentina Non-Insulin Therapies for Diabetes Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Non-Insulin Therapies for Diabetes Revenue by Type (2016-2026)
10.2 Middle East & Africa Non-Insulin Therapies for Diabetes Revenue by Application (2016-2026)
10.3 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Country
10.3.1 Middle East & Africa Non-Insulin Therapies for Diabetes Revenue by Country (2016-2026)
10.3.2 Turkey Non-Insulin Therapies for Diabetes Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Non-Insulin Therapies for Diabetes Market Size and Forecast (2016-2026)
10.3.4 UAE Non-Insulin Therapies for Diabetes Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Non-Insulin Therapies for Diabetes Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Non-Insulin Therapies for Diabetes Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Non-Insulin Therapies for Diabetes Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Non-Insulin Therapies for Diabetes Revenue (USD Million) by Region (2016-2021)
Table 5. Global Non-Insulin Therapies for Diabetes Revenue Market Share by Region (2021-2026)
Table 6. GSK Corporate Information, Head Office, and Major Competitors
Table 7. GSK Major Business
Table 8. GSK Non-Insulin Therapies for Diabetes Product and Solutions
Table 9. GSK Non-Insulin Therapies for Diabetes Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Eli Lilly Corporate Information, Head Office, and Major Competitors
Table 11. Eli Lilly Major Business
Table 12. Eli Lilly Non-Insulin Therapies for Diabetes Product and Solutions
Table 13. Eli Lilly Non-Insulin Therapies for Diabetes Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Sumitomo Dainippon Pharma Corporate Information, Head Office, and Major Competitors
Table 15. Sumitomo Dainippon Pharma Major Business
Table 16. Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Product and Solutions
Table 17. Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Intarcia Therapeutics Corporate Information, Head Office, and Major Competitors
Table 19. Intarcia Therapeutics Major Business
Table 20. Intarcia Therapeutics Non-Insulin Therapies for Diabetes Product and Solutions
Table 21. Intarcia Therapeutics Non-Insulin Therapies for Diabetes Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Servier Corporate Information, Head Office, and Major Competitors
Table 23. Servier Major Business
Table 24. Servier Non-Insulin Therapies for Diabetes Product and Solutions
Table 25. Servier Non-Insulin Therapies for Diabetes Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Pfizer Corporate Information, Head Office, and Major Competitors
Table 27. Pfizer Major Business
Table 28. Pfizer Non-Insulin Therapies for Diabetes Product and Solutions
Table 29. Pfizer Non-Insulin Therapies for Diabetes Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Merck Corporate Information, Head Office, and Major Competitors
Table 31. Merck Major Business
Table 32. Merck Non-Insulin Therapies for Diabetes Product and Solutions
Table 33. Merck Non-Insulin Therapies for Diabetes Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Dong-A Pharmaceutical Corporate Information, Head Office, and Major Competitors
Table 35. Dong-A Pharmaceutical Major Business
Table 36. Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Product and Solutions
Table 37. Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Luye Pharma Group Corporate Information, Head Office, and Major Competitors
Table 39. Luye Pharma Group Major Business
Table 40. Luye Pharma Group Non-Insulin Therapies for Diabetes Product and Solutions
Table 41. Luye Pharma Group Non-Insulin Therapies for Diabetes Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Eurofarma Corporate Information, Head Office, and Major Competitors
Table 43. Eurofarma Major Business
Table 44. Eurofarma Non-Insulin Therapies for Diabetes Product and Solutions
Table 45. Eurofarma Non-Insulin Therapies for Diabetes Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Geropharm Corporate Information, Head Office, and Major Competitors
Table 47. Geropharm Major Business
Table 48. Geropharm Non-Insulin Therapies for Diabetes Product and Solutions
Table 49. Geropharm Non-Insulin Therapies for Diabetes Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Alkem Labs Corporate Information, Head Office, and Major Competitors
Table 51. Alkem Labs Major Business
Table 52. Alkem Labs Non-Insulin Therapies for Diabetes Product and Solutions
Table 53. Alkem Labs Non-Insulin Therapies for Diabetes Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. SatRx Corporate Information, Head Office, and Major Competitors
Table 55. SatRx Major Business
Table 56. SatRx Non-Insulin Therapies for Diabetes Product and Solutions
Table 57. SatRx Non-Insulin Therapies for Diabetes Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 58. Jiangsu Hansoh Pharmaceutical Corporate Information, Head Office, and Major Competitors
Table 59. Jiangsu Hansoh Pharmaceutical Major Business
Table 60. Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Product and Solutions
Table 61. Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 62. Novo Nordisk Corporate Information, Head Office, and Major Competitors
Table 63. Novo Nordisk Major Business
Table 64. Novo Nordisk Non-Insulin Therapies for Diabetes Product and Solutions
Table 65. Novo Nordisk Non-Insulin Therapies for Diabetes Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 66. Emisphere Corporate Information, Head Office, and Major Competitors
Table 67. Emisphere Major Business
Table 68. Emisphere Non-Insulin Therapies for Diabetes Product and Solutions
Table 69. Emisphere Non-Insulin Therapies for Diabetes Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 70. Uni-Bio Science Group Corporate Information, Head Office, and Major Competitors
Table 71. Uni-Bio Science Group Major Business
Table 72. Uni-Bio Science Group Non-Insulin Therapies for Diabetes Product and Solutions
Table 73. Uni-Bio Science Group Non-Insulin Therapies for Diabetes Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 74. Takeda Corporate Information, Head Office, and Major Competitors
Table 75. Takeda Major Business
Table 76. Takeda Non-Insulin Therapies for Diabetes Product and Solutions
Table 77. Takeda Non-Insulin Therapies for Diabetes Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 78. 3SBio Corporate Information, Head Office, and Major Competitors
Table 79. 3SBio Major Business
Table 80. 3SBio Non-Insulin Therapies for Diabetes Product and Solutions
Table 81. 3SBio Non-Insulin Therapies for Diabetes Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 82. Jiangsu Hengrui Medicine Corporate Information, Head Office, and Major Competitors
Table 83. Jiangsu Hengrui Medicine Major Business
Table 84. Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Product and Solutions
Table 85. Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 86. Global Non-Insulin Therapies for Diabetes Revenue (USD Million) by Players (2019-2021)
Table 87. Global Non-Insulin Therapies for Diabetes Revenue Share by Players (2019-2021)
Table 88. Breakdown of Non-Insulin Therapies for Diabetes by Company Type (Tier 1, Tier 2 and Tier 3)
Table 89. Non-Insulin Therapies for Diabetes Players Head Office, Products and Services Provided
Table 90. Non-Insulin Therapies for Diabetes Mergers & Acquisitions in the Past Five Years
Table 91. Non-Insulin Therapies for Diabetes New Entrants and Expansion Plans
Table 92. Global Non-Insulin Therapies for Diabetes Revenue (USD Million) by Type (2016-2021)
Table 93. Global Non-Insulin Therapies for Diabetes Revenue Share by Type (2016-2021)
Table 94. Global Non-Insulin Therapies for Diabetes Revenue Forecast by Type (2021-2026)
Table 95. Global Non-Insulin Therapies for Diabetes Revenue by Application (2016-2021)
Table 96. Global Non-Insulin Therapies for Diabetes Revenue Forecast by Application (2021-2026)
Table 97. North America Non-Insulin Therapies for Diabetes Revenue by Type (2016-2021) & (USD Million)
Table 98. North America Non-Insulin Therapies for Diabetes Revenue by Type (2021-2026) & (USD Million)
Table 99. North America Non-Insulin Therapies for Diabetes Revenue by Application (2016-2021) & (USD Million)
Table 100. North America Non-Insulin Therapies for Diabetes Revenue by Application (2021-2026) & (USD Million)
Table 101. North America Non-Insulin Therapies for Diabetes Revenue by Country (2016-2021) & (USD Million)
Table 102. North America Non-Insulin Therapies for Diabetes Revenue by Country (2021-2026) & (USD Million)
Table 103. Europe Non-Insulin Therapies for Diabetes Revenue by Type (2016-2021) & (USD Million)
Table 104. Europe Non-Insulin Therapies for Diabetes Revenue by Type (2021-2026) & (USD Million)
Table 105. Europe Non-Insulin Therapies for Diabetes Revenue by Application (2016-2021) & (USD Million)
Table 106. Europe Non-Insulin Therapies for Diabetes Revenue by Application (2021-2026) & (USD Million)
Table 107. Europe Non-Insulin Therapies for Diabetes Revenue by Country (2016-2021) & (USD Million)
Table 108. Europe Non-Insulin Therapies for Diabetes Revenue by Country (2021-2026) & (USD Million)
Table 109. Asia-Pacific Non-Insulin Therapies for Diabetes Revenue by Type (2016-2021) & (USD Million)
Table 110. Asia-Pacific Non-Insulin Therapies for Diabetes Revenue by Type (2021-2026) & (USD Million)
Table 111. Asia-Pacific Non-Insulin Therapies for Diabetes Revenue by Application (2016-2021) & (USD Million)
Table 112. Asia-Pacific Non-Insulin Therapies for Diabetes Revenue by Application (2021-2026) & (USD Million)
Table 113. Asia-Pacific Non-Insulin Therapies for Diabetes Revenue by Region (2016-2021) & (USD Million)
Table 114. Asia-Pacific Non-Insulin Therapies for Diabetes Revenue by Region (2021-2026) & (USD Million)
Table 115. South America Non-Insulin Therapies for Diabetes Revenue by Type (2016-2021) & (USD Million)
Table 116. South America Non-Insulin Therapies for Diabetes Revenue by Type (2021-2026) & (USD Million)
Table 117. South America Non-Insulin Therapies for Diabetes Revenue by Application (2016-2021) & (USD Million)
Table 118. South America Non-Insulin Therapies for Diabetes Revenue by Application (2021-2026) & (USD Million)
Table 119. South America Non-Insulin Therapies for Diabetes Revenue by Country (2016-2021) & (USD Million)
Table 120. South America Non-Insulin Therapies for Diabetes Revenue by Country (2021-2026) & (USD Million)
Table 121. Middle East & Africa Non-Insulin Therapies for Diabetes Revenue by Type (2016-2021) & (USD Million)
Table 122. Middle East & Africa Non-Insulin Therapies for Diabetes Revenue by Type (2021-2026) & (USD Million)
Table 123. Middle East & Africa Non-Insulin Therapies for Diabetes Revenue by Application (2016-2021) & (USD Million)
Table 124. Middle East & Africa Non-Insulin Therapies for Diabetes Revenue by Application (2021-2026) & (USD Million)
Table 125. Middle East & Africa Non-Insulin Therapies for Diabetes Revenue by Country (2016-2021) & (USD Million)
Table 126. Middle East & Africa Non-Insulin Therapies for Diabetes Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Non-Insulin Therapies for Diabetes Picture
Figure 2. Global Non-Insulin Therapies for Diabetes Revenue Market Share by Type in 2020
Figure 3. Alpha-glucosidase Inhibitors
Figure 4. Amylin Agonists
Figure 5. Biguanides
Figure 6. Dipeptidyl Peptidase-4 (DPP4) Inhibitors
Figure 7. Glinides / Meglitinides
Figure 8. GLP-1 Analogs / GLP-1 Agonists
Figure 9. Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
Figure 10. Sulfonylureas
Figure 11. Thiazolidinediones
Figure 12. Others
Figure 13. Non-Insulin Therapies for Diabetes Revenue Market Share by Application in 2020
Figure 14. Monitoring Picture
Figure 15. Diagnosis Picture
Figure 16. Treatment Picture
Figure 17. Others Picture
Figure 18. Global Non-Insulin Therapies for Diabetes Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 19. Global Non-Insulin Therapies for Diabetes Revenue and Forecast (2016-2026) & (USD Million)
Figure 20. Global Non-Insulin Therapies for Diabetes Revenue Market Share by Region (2016-2026)
Figure 21. Global Non-Insulin Therapies for Diabetes Revenue Market Share by Region in 2020
Figure 22. North America Non-Insulin Therapies for Diabetes Revenue (USD Million) and Growth Rate (2016-2026)
Figure 23. Europe Non-Insulin Therapies for Diabetes Revenue (USD Million) and Growth Rate (2016-2026)
Figure 24. Asia-Pacific Non-Insulin Therapies for Diabetes Revenue (USD Million) and Growth Rate (2016-2026)
Figure 25. South America Non-Insulin Therapies for Diabetes Revenue (USD Million) and Growth Rate (2016-2026)
Figure 26. Non-Insulin Therapies for Diabetes Market Drivers
Figure 27. Non-Insulin Therapies for Diabetes Market Restraints
Figure 28. Non-Insulin Therapies for Diabetes Market Trends
Figure 29. GSK Recent Developments and Future Plans
Figure 30. Eli Lilly Recent Developments and Future Plans
Figure 31. Sumitomo Dainippon Pharma Recent Developments and Future Plans
Figure 32. Intarcia Therapeutics Recent Developments and Future Plans
Figure 33. Servier Recent Developments and Future Plans
Figure 34. Pfizer Recent Developments and Future Plans
Figure 35. Merck Recent Developments and Future Plans
Figure 36. Dong-A Pharmaceutical Recent Developments and Future Plans
Figure 37. Luye Pharma Group Recent Developments and Future Plans
Figure 38. Eurofarma Recent Developments and Future Plans
Figure 39. Geropharm Recent Developments and Future Plans
Figure 40. Alkem Labs Recent Developments and Future Plans
Figure 41. SatRx Recent Developments and Future Plans
Figure 42. Jiangsu Hansoh Pharmaceutical Recent Developments and Future Plans
Figure 43. Novo Nordisk Recent Developments and Future Plans
Figure 44. Emisphere Recent Developments and Future Plans
Figure 45. Uni-Bio Science Group Recent Developments and Future Plans
Figure 46. Takeda Recent Developments and Future Plans
Figure 47. 3SBio Recent Developments and Future Plans
Figure 48. Jiangsu Hengrui Medicine Recent Developments and Future Plans
Figure 50. Global Non-Insulin Therapies for Diabetes Revenue Share by Players in 2020
Figure 51. Non-Insulin Therapies for Diabetes Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 52. Global Top 3 Players Non-Insulin Therapies for Diabetes Revenue Market Share in 2020
Figure 53. Global Top 10 Players Non-Insulin Therapies for Diabetes Revenue Market Share in 2020
Figure 54. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 55. Global Non-Insulin Therapies for Diabetes Revenue Share by Type in 2020
Figure 56. Global Non-Insulin Therapies for Diabetes Market Share Forecast by Type (2021-2026)
Figure 57. Global Non-Insulin Therapies for Diabetes Revenue Share by Application in 2020
Figure 58. Global Non-Insulin Therapies for Diabetes Market Share Forecast by Application (2021-2026)
Figure 59. North America Non-Insulin Therapies for Diabetes Sales Market Share by Type (2016-2026)
Figure 60. North America Non-Insulin Therapies for Diabetes Sales Market Share by Application (2016-2026)
Figure 61. North America Non-Insulin Therapies for Diabetes Revenue Market Share by Country (2016-2026)
Figure 62. United States Non-Insulin Therapies for Diabetes Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Canada Non-Insulin Therapies for Diabetes Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Mexico Non-Insulin Therapies for Diabetes Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Europe Non-Insulin Therapies for Diabetes Sales Market Share by Type (2016-2026)
Figure 66. Europe Non-Insulin Therapies for Diabetes Sales Market Share by Application (2016-2026)
Figure 67. Europe Non-Insulin Therapies for Diabetes Revenue Market Share by Country (2016-2026)
Figure 68. Germany Non-Insulin Therapies for Diabetes Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. France Non-Insulin Therapies for Diabetes Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. United Kingdom Non-Insulin Therapies for Diabetes Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Russia Non-Insulin Therapies for Diabetes Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. Italy Non-Insulin Therapies for Diabetes Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. Asia-Pacific Non-Insulin Therapies for Diabetes Sales Market Share by Type (2016-2026)
Figure 74. Asia-Pacific Non-Insulin Therapies for Diabetes Sales Market Share by Application (2016-2026)
Figure 75. Asia-Pacific Non-Insulin Therapies for Diabetes Revenue Market Share by Region (2016-2026)
Figure 76. China Non-Insulin Therapies for Diabetes Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Japan Non-Insulin Therapies for Diabetes Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. South Korea Non-Insulin Therapies for Diabetes Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 79. India Non-Insulin Therapies for Diabetes Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 80. Southeast Asia Non-Insulin Therapies for Diabetes Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 81. Australia Non-Insulin Therapies for Diabetes Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 82. South America Non-Insulin Therapies for Diabetes Sales Market Share by Type (2016-2026)
Figure 83. South America Non-Insulin Therapies for Diabetes Sales Market Share by Application (2016-2026)
Figure 84. South America Non-Insulin Therapies for Diabetes Revenue Market Share by Country (2016-2026)
Figure 85. Brazil Non-Insulin Therapies for Diabetes Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 86. Argentina Non-Insulin Therapies for Diabetes Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 87. Middle East and Africa Non-Insulin Therapies for Diabetes Sales Market Share by Type (2016-2026)
Figure 88. Middle East and Africa Non-Insulin Therapies for Diabetes Sales Market Share by Application (2016-2026)
Figure 89. Middle East and Africa Non-Insulin Therapies for Diabetes Revenue Market Share by Country (2016-2026)
Figure 90. Turkey Non-Insulin Therapies for Diabetes Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 91. Saudi Arabia Non-Insulin Therapies for Diabetes Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 92. UAE Non-Insulin Therapies for Diabetes Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 93. Methodology
Figure 94. Research Process and Data Source
世界の糖尿病用非インスリン療法市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Non-Insulin Therapies for Diabetes Market The global Non-Insulin Therapies for Diabetes market size is projected to reach US$ 54930 million by 2026, from US$ 30040 million in 2019, at a CAGR of 8.9% during 2021-2026. With industry-standard accuracy in analysis an…- 世界のインスリンポンプ付属品市場 2021：企業別、地域別、種類・用途別 The Insulin pump Accessories market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regula…
- 世界の植込み型インスリンポンプ市場 2021：企業別、地域別、種類・用途別 The Implantable Insulin Pump market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regula…
- 世界の針なし糖尿病治療市場規模・現状・予測（2021年-2027年） Diabetes is a metabolic disorder in this condition person will have high blood glucose levels than the normal blood glucose. This is mainly due to inadequate insulin production or body cells are unable to respond to the produced insulin in the body or both. Symptoms of Diabetes are hyperglycemic con…
- 世界の針なし糖尿病治療市場規模・現状・予測（2021年-2027年） Diabetes is a metabolic disorder in this condition person will have high blood glucose levels than the normal blood glucose. This is mainly due to inadequate insulin production or body cells are unable to respond to the produced insulin in the body or both. Symptoms of Diabetes are hyperglycemic con…